TC
BCLI

TFS Capital’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

TFS Capital’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,396
Closed -$87K – 39
2017
Q2 		$87K Buy
+1,396
New +$86K 0.03% 561
2015
Q3 		– Sell
-1,956
Closed -$106K – 892
2015
Q2 		$106K Sell
1,956
-800
-29% -$47.7K 0.01% 810
2015
Q1 		$184K Buy
+2,756
New +$174K 0.02% 793

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

TFS Capital's BCLI Position: Q3 2017 in Review

TFS Capital sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2017, closing a stake of 1,396 shares — an estimated $87K sold.

TFS Capital first reported a position in BCLI in Q1 2015 and held it in 3 quarters. The position peaked at $184K in Q1 2015. 32 funds tracked by Wall St. Rank hold BCLI as of Q3 2017.

  • TFS Capital reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 1,396 BRAINSTORM CELL THERAPUTC shares in Q3 2017, an estimated $87K.
  • TFS Capital first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2015 and held it in 3 quarters.
  • TFS Capital's BRAINSTORM CELL THERAPUTC position peaked at $184K in Q1 2015.
  • 32 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.